Our latest research on enhancing immunotherapy efficacy by modulating the tumor immune microenvironment using biodegradable nanoparticles has been published in Acta Biomaterialia. The paper is titled “Degradation-Controlled Synchronization of HIF-2α and MEK Inhibition Using Self-Sealed Porous Silicon Nanoparticles to Reprogram Tumor Immunogenicity.” Juyoung led this study as the first author.

This work represents a key milestone achieved through a successful long-term collaboration with Prof. Junghyun Lee’s laboratory in the Department of Dermatology and Prof. David L. Mack’s laboratory in the Department of Rehabilitation Medicine at the University of Washington (UW) Medical School, stemming from a 4-year visiting research initiative at UW. The study holds significant translational importance as it utilizes FDA-approved drugs delivered via self-sealed porous silicon nanoparticles to achieve synchronized, degradation-controlled release, effectively reprogramming the tumor immune microenvironment. Congratulations to Juyoung and the collaborative team on this remarkable achievement!